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Emerging zoonoses with pandemic potential are a stated priority for the global
health security agenda, but endemic zoonoses also have amajor societal impact
in low-resource settings. Although many endemic zoonoses can be treated,
timely diagnosis and appropriate clinical management of human cases is often
challenging. Preventive ‘One Health’ interventions, e.g. interventions in
animal populations that generate human health benefits, may provide a useful
approach to overcoming some of these challenges. Effective strategies, such as
animal vaccination, already exist for the prevention, control and elimination
of many endemic zoonoses, including rabies, and several livestock zoonoses
(e.g. brucellosis, leptospirosis, Q fever) that are important causes of human
febrile illness and livestock productivity losses in low- and middle-income
countries. We make the case that, for these diseases, One Health interventions
have the potential to be more effective and generate more equitable benefits
for human health and livelihoods, particularly in rural areas, than approaches
that rely exclusively on treatment of human cases.We hypothesize that applying
One Health interventions to tackle these health challenges will help to build
trust, community engagement and cross-sectoral collaboration, which will in
turn strengthen the capacity of fragile health systems to respond to the threat
of emerging zoonoses and other future health challenges. One Health interven-
tions thus have the potential to align the ongoing needs of disadvantaged
communities with the concerns of the broader global community, providing a
pragmatic and equitable approach to meeting the global goals for sustainable
development and supporting the global health security agenda.
This article is part of the themed issue ‘One Health for a changing world:
zoonoses, ecosystems and human well-being’.
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21. Introduction
While outbreaks of emerging zoonoses, such as Ebola virus
disease, galvanize the world’s attention, it is the endemic
zoonoses that still inflict the much greater burden of mor-
tality and morbidity. In a recent review exploring the
associations between zoonoses and poverty, a ranking of
‘important’ zoonoses was made on the basis of human mor-
tality, human morbidity, impact on the livestock sector,
amenability to agriculture-based control, and emergence
or severity of disease in people [1]. The 13 top-ranked zoo-
noses were responsible for 2.2 million human deaths and
2.4 billion cases of illness every year [1]. Notwithstanding
the devastating impacts of the recent West African Ebola dis-
ease epidemic, it is salutary to note that, every year, rabies
and leptospirosis are estimated to cause five times as many
human deaths, with an estimated 59 000 people dying from
each of these diseases annually [2,3]. Other endemic zoonoses
may well have impacts of comparable magnitude [1], but in
many cases, we lack the data to define and demonstrate
these impacts fully.
There are several reasons why, despite causing relatively
high mortality and morbidity, endemic zoonoses do not
trigger as much international concern as emerging zoonotic
diseases, such as those caused by Ebola virus, highly
pathogenic avian influenza virus or severe acute respiratory
syndrome-coronavirus. First, for most endemic zoonoses,
there is little potential for sustained transmission in human
populations and therefore little risk of transboundary spread
to high-income countries through human movements and con-
tacts. Second, measures for the prevention, treatment and
control of endemic zoonoses are often available to protect
people and animals in high-income countries and the disease
burden is much less substantial than in neglected commu-
nities. These factors reduce immediate awareness and
concern about disease risk at international level, which in
turn impacts on the perceived need to prioritize investments
for disease control and prevention in low-income settings.
This lack of prioritization is further exacerbated by pro-
blems of disease visibility. Many endemic zoonoses present
with non-specific clinical signs in both people and animals
and are easy to misdiagnose on clinical grounds [4]. These
zoonoses are poorly recognized by healthcare providers
[5,6] and are often overlooked in differential diagnoses.
Well-validated point-of-care diagnostic tests are rarely avail-
able, and diagnosis of chronic stages or sequelae of
infections is often difficult. The pattern of under-recognition
of zoonoses persists, despite a growing body of evidence
that many zoonoses are important causes of common
human disease syndromes, such as undifferentiated fever,
in both Africa and Asia [6–12].
While several endemic zoonoses have been termed
‘neglected’ [13], the issue of neglect arises not as a result
of lack of recognition of or research on the pathogens per
se. Most of these zoonoses have long been recognized in
the medical and veterinary literature, are well understood
and are often well controlled in high-income countries.
Instead, their neglect occurs because the risks and burden
of these zoonoses fall heavily on disadvantaged and vul-
nerable communities with little political voice in low- and
middle-income countries (LMICs) [13–15]. The term ‘unat-
tended’ diseases, as used in the Global Goals for
Sustainable Development (SDG 3) [16], may better reflectthe lack of attention given to diseases affecting disadvan-
taged communities, as well as the ineffective,
inappropriate or lack of application of available measures
for disease control and prevention.
While people in all communities can be exposed to zoo-
notic infections, the greatest disease burden falls on the
estimated one billion poor livestock keepers in Asia and
Africa [1]. There are several reasons why it is the rural poor
who are most vulnerable to exposure, infection and the
downstream consequences of endemic zoonoses [13,14,17]:
(i) because close contact with animals and traditional food
consumption practices heighten exposure risks; (ii) because
zoonotic diseases often affect livestock production, so it is
people in poor livestock-dependent communities who are
highly vulnerable to the impacts of zoonoses on livelihoods,
food security and wellbeing; (iii) because the rural poor gen-
erally have limited access to high-quality human and animal
health services for clinical care and treatment of illness; and
(iv) because there are numerous social, political and econ-
omic issues that affect the ability of individuals to act in
particular ways (individual agency), so the poor often have
limited capacity to mitigate or manage disease risks.
Figure 1 illustrates those countries in Africa, particularly in
East and West Africa, where risks and vulnerabilities are
likely to be particularly intense, characterized by areas
where there is convergence of high livestock and domestic
dog densities, a high proportion of the population engaged
in agriculture and poor provision of health services.2. A global rationale for prioritizing endemic
zoonoses
Global health security is a shared responsibility but profound
weaknesses in health systems currently limit the capacity of
LMICs for effective healthcare provision, disease surveillance
and outbreak response. Several international health initiatives
address zoonoses, but many of these, including the Inter-
national Health Regulations [20] and the Global Health
Security Agenda (GHSA) [21], focus primarily on emerging
zoonoses that threaten the broader global community.
The case has been made that a global surveillance system
established for emerging zoonotic diseases could be readily
improvised to address endemic diseases [22]. However,
even with substantial investments made during outbreaks
of highly pathogenic avian influenza, laboratory diagnostic
capacity remains limited and concentrated in a few cities,
and there remains a severe shortage of health professionals
and workers, particularly in rural areas [23]. Thus, despite
large-scale investments in surveillance for diseases such as
highly pathogenic avian influenza, fewer than 20% of
United Nations member states are able to effectively
implement the International Health Regulations [24]. Once
the immediate threat of an emerging disease has passed,
and crisis funding and donor support removed, it may be dif-
ficult for governments in low-income countries to maintain
support for the staff, skills and laboratory infrastructure
needed to detect and respond to rare emerging disease out-
breaks that are of little day-to-day concern to their
populations.
To achieve effective global surveillance systems, we
suggest that a complementary approach also needs to be con-
sidered—that is, a global surveillance and control system
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Figure 1. Maps showing African country-level data for: (a) percentage of population involved in agriculture—data from FAO [18]; (b) healthcare service provision
shown by the number of people per physician—data from WHO [19]; (c) density of ruminant livestock (individuals km22)—data from FAO [18]; (d ) density of
domestic dogs (dogs km22)—data from Hampson et al. [2]. (Online version in colour.)
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
372:20160168
3established to address endemic diseases that are acknowl-
edged as priorities in developing countries can form the
platform for a sustainable and effective surveillance system
for early detection and response to emerging disease threats.
The lessons of past disease outbreaks and response efforts
show that the adaptation of existing networks and capacities
to deal with new threats is crucial. This approach has recently
been advocated in the regional meeting of Health and Agri-
culture Ministries in Latin America on the management of
zoonose risks, with emerging, re-emerging and endemic zoo-
noses considered as linked priorities, and with integrated
surveillance and coordinated governance key pillars of
strengthening One Health capability [25]. We hypothesize
that building systems to tackle endemic zoonotic challenges
can provide a useful mechanism to build the core capacities
that can then be adapted and built upon to achieve effective
coordinated responses to future disease threats.The engagement of several African countries in the GHSA
zoonoses action package may provide a useful test of this
hypothesis. While the focus of the GHSA is on preventing,
detecting and responding to emerging zoonotic disease out-
breaks that are of global concern, the GHSA zoonoses
action package specifically advocates strengthening surveil-
lance through One Health approaches and by focusing on
the five zoonotic diseases or pathogens of ‘greatest public
health concern’ [21]. For example, following a prioritization
exercise that was conducted in Ethiopia, rabies, anthrax,
brucellosis, leptospirosis and echinococcus were identified
as the five zoonoses of greatest concern in Ethiopia, and rec-
ommendations were made for strengthening intersectoral
surveillance and interventions against these diseases, with
regular review to address new emerging zoonotic disease
threats [26]. The implementation of these recommendations
in Ethiopia should provide a useful indication as to whether
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4and how strengthening of disease surveillance systems that
address endemic zoonotic disease priorities will prepare the
country to more effectively address emerging disease threats.
We have previously suggested that approaches focused on
endemic zoonoses not only offer a pragmatic approach to over-
coming existing barriers that limit global capacity for emerging
disease surveillance, but also address inequalities in global
health by delivering benefits to affected people in low-
income countries [27]. This approach aligns closely with the
recently established aims of the Global Goals for Sustainable
Development within Goal 3. These include a commitment to
accelerating progress not only in relation to diseases that
are of widespread international concern (such as HIV/AIDS,
tuberculosis and Ebola virus disease) but equally to those
that affect disadvantaged communities, i.e. the neglected or
unattended diseases affecting developing countries (Target
3.3) [16]. Goal 3 further combines a commitment to strengthen-
ing capacity of all countries, in particular developing
countries, for early warning, risk reduction and management
of national and global health risks (Target 3.d) with a target
of achieving universal health coverage and access to affordable
essential medicines and vaccines for all (Target 3.8) [16].
Within the Latin America region, One Health approaches
that address both endemic and emerging disease are now
being advocated specifically in the context of achieving these
global goals for sustainable development [25].3. Community trust, engagement and
empowerment
In tackling zoonotic disease threats, technical capabilities
such as diagnostic tests have often been prioritized over
organizational capacities, such as communication, trust
building, political advocacy and leadership, that are critical
for improving institutions and systems [28]. However,
among several important lessons learned, the West Africa
epidemic of Ebola virus disease highlighted the critical
need for enhancing community trust, engagement and own-
ership [23,29]. Intersectoral governance mechanisms have
often been established in response to crises to address specific
risks. However, trust between stakeholders and communities
to support and build effective health systems cannot be
spontaneously generated. Trust is built and is founded on
experience, and can be developed through planned and regu-
lar interactions of all stakeholders, including representatives
of heterogeneous communities, to address endemic zoonotic
risks. Sustained investments and efforts to manage endemic
zoonoses which deliver public health and livestock pro-
duction benefits, train people and engage with communities
can create a platform upon which relationships and trust
can be built for more coordinated emergency responses.4. Power, politics and agency
A major problem in tackling many zoonoses is that diagnosis
and clinical management of human cases can be challenging,
costly and usually requires access to reliable and high-quality
medical services. While improvements in diagnosis and clini-
cal management are urgently needed, we also need to
understand the specific, economic, political and social
forces that constrain the agency of individuals to act inparticular ways. One Health can provide important under-
standing of the systemic reasons why some individuals are
more affected by zoonoses than others because of its focus
on animal–human interactions and on identifying which
humans are interacting with which animals under what
conditions [30]. These previously under-recognised vulner-
abilities to disease intersect with socio-economic power
relations and other structural factors, which in turn constrain
health-seeking behaviour. For example, a study of women’s
experiences when seeking treatment for fever, which was car-
ried out in a deprived urban community in Tanzania,
highlighted the sense of helplessness experienced by these
women when negotiating the health system:I have a fear of the payment, and not of the sickness. Treatment
exists, good treatment that will cure quickly, but you worry you
will not be able to find the money in time because a fever does
not wait for you. You worry if you will be able to find the
money to get treatment before the patient dies [31, p. 128].Where deaths occurred, ‘user fees’, ‘poverty’ and ‘inequality’
would not appear on death certificates, but a social autopsy
would inevitably reveal these as conspiring factors in such
fatalities [31]. Other problems that were frequently reported
included waiting for treatment, while other, less-disadvan-
taged people ‘queue-jumped’, and having to provide bribes
to be seen by doctors. These women’s experiences demon-
strate that poverty is more than just a lack of resource to
make better decisions; they also point to the ways in which
the sense of themselves as capable agents was being
eroded. It did not matter what action these women took,
the system appeared always to set them aside while others
were privileged.
In considering the well-recognized links between poverty
and ill-health, Farmer [32,33] emphasizes the importance of
seeing beyond a causality that results from either failures in
individual or household knowledge and behaviour, or from
uncritical, relativistic understandings of cultural difference:Exaggeration of patient agency is particularly marked in the bio-
medical literature, in part because of medicine’s celebrated focus
on individual patients, which inevitably desocializes [33, p. 258].Farmer argues that sickness among the poor can be under-
stood as the result of ‘structural violence’, historically and
geographically specific, economic, political and social forces
which work to constrain the agency of individuals to act in
particular ways [32,33]. Whether this refers to government
or international agency, policy, gender relations or capitalist
relations playing out on a variety of scales, such structural
processes create conditions that empower certain individuals
with agency, while limiting the sense of capacity for others.
Equitable delivery of health services is clearly necessary to
reduce the toll of structural violence.
In a noteworthy case study, Chami et al. [34] discuss how
power structures have played out in mass drug adminis-
tration (MDA) campaigns in Uganda, impacting not only
people seeking care for acute illness but also on delivery of
anthelminthic drugs against schistosomiasis and soil-trans-
mitted helminths. Socioeconomic status and minority group
affiliation were key determinants of who received drugs
and who did not, with people of low socioeconomic status
and those in minority tribes or religions having less access
to drugs. The contrast was particularly marked across house-
holds with or without members in the current or former
village government. The failure to recognize how poverty—
shaped by structural, political, socio-cultural and economic
rstb.
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tackling inequalities through One Health
interventions
The Commission on Social Determinants of Health estab-
lished by the World Health Organization in 2005 has the
remit of promoting health equity and of fostering a global
movement to achieve it [35]. A driving principle of the
work of this commission is that ‘No country or region
should have to live with levels of ill-health that are avoidable’
[36]. Although treatments are available for several endemic
zoonoses, it is the disadvantaged and poor who are being
‘left behind’ when approaches rely on clinical management.
However, many endemic zoonoses are entirely or largely pre-
ventable through One Health measures targeted at animal or
environmental reservoirs and infection sources and these
preventive approaches offer several advantages.
One Health interventions that effectively reduce the force
of infection from the animal or environmental reservoir
convey benefits to all who are epidemiologically connected
to the source of infection without regard to socioeconomic
status—the benefit cannot be ‘purchased’ or socially distorted
to the detriment of the poor. Social factors will always impact
on the accessibility of healthcare but interventions targeted to
prevent zoonoses at source will help buffer the impacts of
these social drivers of inequality in healthcare provision, par-
ticularly in rural communities in Africa, where 83% of people
are not covered by essential health services [37] and where
people are also at greatest risk from endemic zoonoses [1,14].
In public health, the principle that preventive measures
can be more effective and equitable than relying on treat-
ments or cures is well accepted. When implemented on a
national level, vaccination has been one of the most equitable
low-cost, high-impact public health measures, saving
millions of lives annually in LMICs [38]. However, this prin-
ciple has been embraced less when the public health
intervention is targeted at the animal population, even
when the intervention has shown to be feasible and cost-
effective, as in the case of mass vaccination of dogs against
rabies, discussed below. One Health provides a useful frame-
work for broadening the scope of potential interventions that
might be considered by public health agencies, particularly in
rural communities. In the case of livestock-mediated zoo-
noses, further advantages of One Health interventions
relate to the added benefits to human health and livelihoods
generated through improvements to livestock health and
productivity.
One Health interventions advocate close intersectoral
cooperation, interdisciplinary expertise and the involvement
and empowerment (and not simply, engagement) of multi-
ple stakeholders [39]. Thus, although few examples of
such comprehensive One Health implementation exist,
they not only provide a useful framework for addressing
the types of disease problem that involve complex inter-
actions between people, animals and the environment, but
also offer a way to develop and implement more effective,appropriate and acceptable strategies for disease control
and prevention.6. Rabies as a case study
A clear example of the value of One Health interventions is
provided by approaches to the prevention of human rabies
deaths. Human rabies is 100% preventable through two
complementary measures: first, post-exposure prophylaxis
(PEP), which involves administration of rabies immunoglo-
bulin and a multi-dose course of rabies vaccination to
people bitten by suspected rabid animals; second, mass vac-
cination of animal reservoirs (primarily domestic dogs, the
reservoir in the vast majority of human cases), which reduces
the risk of human exposure and can ultimately result in rabies
virus elimination.
While PEP is highly effective in preventing deaths in
people exposed to the virus, many challenges remain for
poor people in remote, rural communities in accessing and
completing PEP regimens [40,41]. Delays in receiving the
first dose of vaccine can all result in fatal outcomes, and
occur as a result of vaccine being available only in larger
clinics, a generally poor transport infrastructure, and/or the
need to raise cash to cover medical and transport costs.
In rural Tanzania, where most people still live on less than
US$2 per day, patients would need to spend over US$100
to complete WHO recommended PEP schedules [41].
These challenges are compounded by intermittent vaccine
shortages, particularly at rural health facilities, which further
contribute to delays in patients receiving PEP and their
inability to complete full schedules [42].
The realities of current approaches to the management of
rabies exposures are revealed by data on the outcome of
rabies exposures in 844 people from detailed contact-tracing
studies [40] conducted in Tanzania from 1996 to 2016.
Eighty individuals were recorded to have died from rabies,
71 (89%) of whom had not received any PEP at all, and
none of the remaining nine had received a full course. The
critical need for prompt PEP administration is shown by
four rabies victims who developed rabies despite a delay of
only 1 day in receiving the first vaccine dose. The poignancy
of these preventable deaths is highlighted by two of these
cases where patients had reported immediately to health
facilities, but faced health system delays in receiving the
first vaccine dose, with fatal consequences.
Rabies also illustrates the critical importance of connecting
human and animal health services in the implementation of
cost-effective preventive measures. Human deaths can be pre-
vented by a combination of prompt administration of PEP
and mass vaccination of domestic dog reservoirs, but the
relative levels of investment in these two arms of prevention
are often mismatched. In Asia, for example, the incidence of
human rabies cases is much higher than in Latin America,
despite the elevated levels of per capita expenditure on
human PEP provision in Asia (figure 2). Here, even though
health sector expenditure on PEP is very high (with US$ 1.3
billion of direct costs spent annually on PEP in Asia), poor
people are still dying from rabies due to lack of access to
health services with PEP. Conversely, many doses of PEP
are given to animal-bite victims who will have had no
rabies exposure, often in relatively affluent urban areas. By
contrast, measures to prevent rabies at source (i.e. through
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Figure 2. Scheme illustrating the relative expenditure on human rabies PEP and mass vaccination of dogs in relation to dog vaccination coverage and the incidence
of human rabies deaths in Africa, Asia and Latin America. Data from Hampson et al. [2].
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6mass dog vaccination) protect both the rich and the poor,
casting a wider ‘safety net’ than can be achieved by focusing
on management of human exposures alone and cost con-
siderably less. In Latin America, for example, even modest
investments in mass dog vaccination (US$ 61million per
year, representing approximately 20% total expenditure on
rabies prevention) [2] have been highly effective in prevent-
ing human rabies deaths, with the region on the brink of
eliminating dog rabies as a human health problem [43].
7. Zoonoses causing human febrile illness
The benefits of One Health preventive measures extend well
beyond rabies and are likely to apply to many livestock
zoonoses, including anthrax, brucellosis, leptospirosis, toxo-
plasmosis, Q fever and Rift Valley fever, all diseases for
which livestock vaccines are available. As is the case with
rabies, livestock zoonoses occur widely in LMICs, but
remain largely ‘invisible’, with frequent mismanagement of
animal and human cases contributing to a vicious cycle of
ill-health and poverty [4].
Several livestock zoonoses—brucellosis, leptospirosis,
Q fever and rickettsioses—which are known to occur across
Africa [44–48] have been identified as causes of febrile illness
in both adults and children in East and West Africa and
southeast Asia [6,7,9,11,49–54]. Illnesses caused by these zoo-
notic pathogens are often difficult to diagnose and are
frequently misdiagnosed: the clinical symptoms and signs
are often non-specific, and easily mistaken for malaria [6];
laboratory confirmatory tests are rarely available; healthcare
provider awareness is generally low [5]; and patients often
present at hospital only in the later stages of infection when
diagnostic confirmation is much more challenging. As
malaria transmission declines in many parts of Africa
[51,55], the importance of zoonoses as causes of non-malaria
febrile illness is becoming more apparent. For example, in a
study involving 870 patients hospitalized with fever in north-
ern Tanzania [6], bacterial zoonoses, which were not initially
considered by clinicians in any cases, were confirmed as acause of disease in 26.2% of cases. Malaria, although clini-
cally diagnosed in the majority of cases (60.7%), was
confirmed as the cause of fever in only very few (1.6%).
While the relative contribution of different zoonoses to the
aetiology of febrile illness varies by location, livestock-associ-
ated zoonoses have been consistently identified in several
recent studies from East Africa. For example, leptospirosis
and Q fever were confirmed in a small number of cases of
systemic febrile infections in children in one outpatient
study in Tanzania [51], and in a much higher proportion of
febrile children in an outpatient study from a different
region, also in Tanzania (with 11.6% patients diagnosed
with presumptive acute leptospirosis, 13% with confirmed
leptospirosis and 22.4% with presumptive brucellosis) [11].
For most zoonoses that have been implicated as significant
causes of human febrile illness, reliable point-of-care diagnos-
tic tests are not available to support clinical management of
cases. While these tests are urgently needed, challenges are
still likely to remain in application and interpretation of diag-
nostic test results. Many patients will experience delays in
reaching health facilities [56] and even with the best tests,
pathogen detection in clinical samples can be very difficult.
A further concern relates to the apparently high levels of
prior antimicrobial use among febrile patients presenting to
health facilities, which may compromise capacity to detect
some bacterial infections. In an analysis of patients presenting
with acute leptospirosis in Tanzania, urinary antibacterial
activity was detected by bioassay in 31 (64.6%) of 48 cases,
and is likely to have contributed to the inability of PCR diag-
nostic tests to detect infection in either plasma or urine
samples at the time of presentation [57].
While point-of-care serological tests are available for some
zoonoses, such as brucellosis, many challenges remain in
the interpretation of results, including problems associated
with the poor performance of tests for diagnosing acute
cases and the high levels of background exposure in many
livestock-keeping communities, which complicates interpret-
ation of results based on a single serological test [58,59]. The
likelihood of misdiagnosis and over-diagnosis of brucellosis
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example of livestock vaccination
Although a wide range of potential interventions may be
considered based on a One Health rationale, particular
opportunities exist in relation to livestock vaccination
strategies in Africa, not only for improving livestock pro-
ductivity and livelihoods, but also for tackling the
preventable human health burden of endemic zoonoses.
Several vaccines exist and are available to prevent many of
the widely occurring livestock-associated zoonoses, and
although they have been adopted in more intensive farming
systems in high- and middle-income countries, they are not
widely used in Africa or other low-income contexts.
Livestock vaccination against brucellosis and leptospiro-
sis has been effective in reducing the burden of disease in
many parts of the world. Vaccination of sheep and goats
is the mainstay of current national brucellosis control and
elimination strategies that are being implemented across
Eastern Europe and Central Asia [60], with substantial
declines in small ruminant and human disease documen-
ted in Azerbaijan, Kyrgyzstan, Macedonia and vaccinated
regions of Tajikistan [60]. In some countries where small
ruminant vaccination has been implemented, bovine brucello-
sis has also been reduced (e.g. Bosnia and Herzegovina,
Kyrgyzstan), indicating that a greater proportion of bovine bru-
cellosis is attributable to Brucella melitensis infection than is
commonly considered [60]. These outcomes are consistent
with findings from Tanzania that implicate sheep and goats
as the likely source of infection in both people and cattle [61].
In Mongolia, small ruminant vaccination has also been shown
to be a highly cost-effective strategy when considering both
human health benefits and livestock production gains [62].
Vaccination of cattle against leptospirosis is widely
practiced in intensive cattle dairy farms in Europe, North
America and Australasia to reduce the reproductive and
milk production losses associated with Leptospira infection,
providing economic benefits to the farmer [63]. However,
little information is available as to the broader population-
level impacts of human health benefits of livestock vacci-
nation schemes, and this remains an important gap that
needs to be addressed [64].
Although there are few formal livestock vaccination pro-
grammes against Q fever, vaccination of cattle has been
shown to be effective in reducing abortions and bacterial
shedding in cattle under experimental conditions in Europe,
and the long-term effectiveness of different vaccination strat-
egies in an intensive dairy herd has been explored through
modelling approaches [65]. During the 2007–2010 Q-fever
outbreak in the Netherlands, livestock vaccination was also
used for the first time with the objective of reducing the
number of human Q-fever cases [66].
While existing vaccines offer great potential for prevent-
ing a wide range of livestock zoonoses that are widespread
across Africa and other LMICs, many questions still remain
as to the design, evaluation and implementation of such
interventions. Livestock vaccination interventions cannot be
rolled out uncritically and there may be occasions wherevaccination efforts could have negative impacts. This might
occur, for example, if vaccination results in an increase in
the average age of an infection and might cause more repro-
ductive losses in sexually mature animals than in situations
where individuals become exposed and acquire immunity
at a younger age.
Human and veterinary vaccination programmes are eval-
uated in very different ways [67]. While methods are now
well established for the development and evaluation of com-
plex human health interventions [68], these approaches have
rarely been employed for interventions focusing on animal
populations, even when these are designed to have human
health benefits and outcomes. The added dimension of
human–animal interaction inevitably adds complexity to
the design of One Health interventions, and this is further
compounded by the complex epidemiology of most livestock
zoonoses—a taxonomically diverse group of pathogens, often
comprising multiple subtypes of related pathogens circulat-
ing in multiple host species and with multiple modes of
transmission.
Key questions in the design of vaccination programmes
relate to the identification of target populations and individ-
uals for vaccination, age at vaccination, vaccination coverage
targets, understanding perceptions and potential barriers to
uptake of vaccination, and sustainability of vaccination pro-
grammes to deliver public health benefits. For example,
uptake may be compromised if animals identified for vacci-
nation under epidemiologically optimal strategies are not
the same as those considered by owners as the most valuable
(e.g. in terms of traction power, food provision or social
value). Household-level decisions will also need to be made
as to how to balance potential costs for healthcare and treat-
ment against recurring costs of preventive measures. These
decisions will be particularly difficult for interventions
directed at disease syndromes with multiple aetiologies,
such as febrile illness, when the links between animal infec-
tion and human disease may be poorly appreciated, and
the impact of any single intervention will only reduce a pro-
portion of the overall burden of the disease syndrome (box 1).
As for all preventive measures, One Health interventions
will be most equitable when delivered at population level.
This poses several challenges for interventions based on live-
stock vaccination, which tend to focus on economic benefits
from improved livestock productivity. National campaigns
and government investment in livestock disease control are
usually limited to notifiable and transboundary livestock dis-
eases, and most countries lack coordinated programmes for
large-scale control of endemic diseases, including many zoo-
noses [67]. Even where attention is focused on control of
animal diseases for improving public health and rural devel-
opment, current policies emphasize private sector
involvement, with attention being given to innovative finan-
cing mechanisms, such as Development Impact Bonds [73],
as well as product and market development to facilitate
and support uptake by smallholder farmers [74]. However,
if One Health interventions have to be sustained only or
largely by direct payments from animal owners, they
are unlikely to help overcome existing inequalities that dis-
advantage the rural poor in relation to affordability or
access to health services. To achieve successful control of
many zoonoses (e.g. brucellosis) [70] and the population-
level benefits that would address existing health inequalities,
careful consideration clearly needs to be given to the balance
Box 1. Brucellosis—a case study.
Brucellosis, caused by several species of the genus Brucella, is a debilitating human disease and cause of substantial livestock
productivity losses globally, particularly in endemic countries [69]. Different Brucella species are associated with different
animal hosts and people are most commonly infected through contact with diseased animals or consumption of infected
animal products [70]. Brucellosis has been effectively controlled in many countries through strategies that include livestock
vaccination, test-and-slaughter and sanitation measures. However, these have yet to be widely deployed in many African
countries or other LMICs. Live attenuated vaccines including Brucella abortus strains (S19 and RB51) in cattle and B. melitensis
Rev 1 in sheep and goats have been used successfully, but none of the current vaccines can protect all host species against all
Brucella species. Safety issues also remain, and little is known about the use of vaccines in ‘non-target’ species, despite the
possibility of cross-species infection and cross-protection [71].
In many low-income settings, questions also remain as to the design of optimal vaccination strategies, including whether
to vaccinate against B. abortus, B. melitensis, other Brucella species or multiple species, which host species to vaccinate and
whether specific age and sex subgroups should be targeted. In East Africa, both B. abortus and B. melitensis are present,
but the degree to which their epidemiology overlaps in mixed livestock systems is largely unknown. Although emphasis
is increasingly being placed on private sector incentives, government involvement is likely to be necessary for successful con-
trol of brucellosis in endemic areas [72]. National programmes can be highly cost-effective when the costs and benefits for
human health and livestock sectors are both considered [62], but achieving an appropriate distribution of investments
and benefits across sectors and among stakeholders remains challenging.
A key issue for brucellosis, and many endemic zoonoses, relates to poor ‘appreciability’ of diseases, particularly those that
cause non-specific disease syndromes, such as human febrile illness and livestock abortion. This is likely to affect the invest-
ments that individuals, communities and stakeholders are willing to make in interventions. In contrast to mass dog
vaccination strategies against rabies, which result in rapid, tangible benefits that are recognized by communities (i.e. the dis-
tinctive and visible cases of rabies disappear), control of brucellosis may be less readily appreciable. Even if successful, cases
of fever in people and livestock abortion will still occur, and the interval between the intervention and any impact is likely to
be prolonged. Understanding and clear communication of the multi-factorial causes of common disease syndromes (as
experienced by affected communities) is crucial to ensure that expectations of any intervention are realistic and the likely
outcomes clearly communicated.
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8of private and public investment, to ensure sustainability and
equity and to justify the use of scarce public resources.9. Implementation and scaling-up of animal
vaccination strategies
To achieve population-level benefits, particular care will be
needed to avoid suboptimal vaccination outcomes, both in
terms of vaccination coverage and completeness. For effective
control of rabies, for example, it is increasingly clear that sus-
tained, contiguous and large-scale programmes are needed,
as even small pockets of low vaccination coverage (involving
less than 0.5% of the dog population) can significantly
hamper progress [75]. Even where the cost-effectiveness
of One Health strategies has been demonstrated, for exam-
ple, in relation to mass rabies vaccination of dogs in Africa
[76,77], sheep and goat vaccination against brucellosis in
Mongolia [62] and control of human African trypanosomiasis
in Uganda [13], barriers remain to scaling-up.
Increasing attention is being paid to opportunities for
integrating platforms for delivery of health interventions,
with international health agencies focusing on the impor-
tance of strengthening health systems to achieve equitable
delivery of health services, rather than developing multiple
vertical programmes for specific diseases [78]. It is recognized
that establishing independent delivery efforts for specific dis-
eases can lead to fragmentation, and that coordination across
sectors is needed to strengthen health systems. In Tanzania,
these ideas are being explored through a programme investi-
gating whether the reach and cost-effectiveness of MDA
targeting soil-transmitted helminths in children and massvaccination of domestic dogs against rabies can be improved
through integration. Adopting One Health approaches, the
project aims to break down traditional barriers that exist
between veterinary and human health interventions, and
build on the community trust achieved through the provision
of a common good (effective control of rabies) in order to
achieve cost savings, develop synergies and improve the
effectiveness of both interventions. Further opportunities to
establish co-delivery across a range of health interventions
exist, not only for integrating control measures against sev-
eral different zoonoses [73], but also for cross-linkages with
public health interventions, such as water, sanitation and
hygiene (WASH) programmes, and joint delivery of public
health and veterinary services, particularly in remote or
nomadic rural communities [79].10. Conclusion
We make the case that One Health interventions that deploy
existing tools, such as animal vaccination, to mitigate the
impacts of endemic zoonoses can provide a pragmatic
approach to achieving multiple objectives for global health.
One Health interventions have the potential to overcome
some of the existing social, political and economic challen-
ges that constrain healthcare delivery in disadvantaged
communities in Africa and deliver more equitable and cost-
effective control of the endemic and neglected zoonoses
that currently exert a substantial, although poorly recognized,
burden of human and animal disease. Further, these
approaches have the potential to enhance capacity for
responding to emerging zoonotic disease threats through
rstb.royalsocietypublishing.o
9improved cross-sectoral collaboration, community engage-
ment and the building of trust that comes through a shared
sense of common good.
Authors’ contributions. All authors contributed to the conception of the
study, drafting of the article and critically revising it for intellectual
content. All authors have given final approval of the version sub-
mitted. S.C., J.E.B.H., K.H., J.A.C., R.R.K., J.S., B.T.M., M.P.R., A.L.,
L.W. and K.J.A. were involved in acquisition of previously published
data that were presented in the article.
Competing interests. We declare we have no competing interests.Funding. This research was supported by the UK Biotechnology and
Biological Sciences Research Council (BB/J010367/1) and the UK
Zoonoses and Emerging Livestock Systems Initiative (BB/L017679/
1, BB/L018926/1 and BB/L018845/1) (S.C., J.E.B.H., J.S., J.B., A.D.,
J.A.C., W.A.d.G., R.R.K., T.K., D.T.H., B.T.M., E.S.S., L.W.). The Well-
come Trust provided supported for K.H. and A.L. (095787/Z/11/Z)
and K.J.A. (096400/Z/11/Z). The US National Institutes of Health
provided support for J.A.C. (R01AI121378) and M.P.R.
(R01AI121378, K23AI116869).
Acknowledgements. We thank Mary Ryan for helpful comments on the
manuscript.rg
Phil.TrReferencesans.R.Soc.B
372:201601681. Grace D et al. 2012 Mapping of poverty and likely
zoonoses hotspots. Zoonoses Project 4. Report to the
UK Department for International Development.
Nairobi, Kenya: International Livestock Research
Institute. See http://hdl.handle.net/10568/21161.
2. Hampson K et al. 2015 Estimating the global
burden of endemic canine rabies. PLoS Negl. Trop.
Dis. 9, e0003709. (doi:10.1371/journal.pntd.
0003709)
3. Costa F et al. 2015 Global morbidity and mortality
of leptospirosis: a systematic review. PLoS Negl.
Trop. Dis. 9, e0003898. (doi:10.1371/journal.pntd.
0003898)
4. Halliday JE, Allan KJ, Ekwem D, Cleaveland S,
Kazwala RR, Crump JA. 2015 Endemic zoonoses in
the tropics: a public health problem hiding in plain
sight. Vet. Rec. 176, 220–225. (doi:10.1136/vr.
h798)
5. Zhang HL et al. 2016 Mixed methods survey of
zoonotic disease awareness and practice among
animal and human healthcare providers in Moshi,
Tanzania. PLoS Negl. Trop. Dis. 10, e0004476.
(doi:10.1371/journal.pntd.0004476)
6. Crump JA et al. 2013 Etiology of severe non-malaria
febrile illness in Northern Tanzania: a prospective
cohort study. PloS Negl. Trop. Dis. 7, e2324. (doi:10.
1371/journal.pntd.0002324)
7. Suttinont C et al. 2006 Causes of acute,
undifferentiated, febrile illness in rural Thailand:
results of a prospective observational study. Ann.
Trop. Med. Parasitol. 100, 363–370. (doi:10.1179/
136485906X112158)
8. Suputtamongkol Y, Rolain JM, Losuwanaruk K,
Niwatayakul K, Suttinont C, Chierakul W, Pimda K,
Raoult D. 2003 Q fever in Thailand. Emerg. Infect.
Dis. 9, 1186–1187. (doi:10.3201/eid0909.030086)
9. Mayxay M et al. 2013 Causes of non-malarial
fever in Laos: a prospective study. Lancet Glob.
Health 1, e46–e54. (doi:10.1016/s2214-
109x(13)70008-1)
10. Susilawati TN, McBride WJ. 2014 Acute
undifferentiated fever in Asia: a review of the
literature. Southeast Asian J. Trop. Med. Public
Health 45, 719–726.
11. Chipwaza B, Mhamphi GG, Ngatunga SD, Selemani
M, Amuri M, Mugasa JP, Gwakisa PS. 2015
Prevalence of bacterial febrile illnesses in children inKilosa district, Tanzania. PLoS Negl. Trop. Dis. 9,
e0003750. (doi:10.1371/journal.pntd.0003750)
12. Chikeka I, Dumler JS. 2015 Neglected bacterial
zoonoses. Clin. Microbiol. Infect. 21, 404–415.
(doi:10.1016/j.cmi.2015.04.022)
13. WHO. 2006 The control of neglected zoonotic
diseases: a route to poverty alleviation. In Report of
a joint WHO/DfID-AHP Meeting, 20–21 September,
2005. Geneva, Switzerland: World Health
Organization. See http://www.who.int/zoonoses/
Report_Sept06.pdf.
14. Molyneux D et al. 2011 Zoonoses and
marginalised infectious diseases of poverty: where
do we stand? Parasit. Vectors 4, 106. (doi:10.
1186/1756-3305-4-106)
15. Seimenis A. 2012 Zoonoses and poverty—a long
road to the alleviation of suffering. Vet. Ital. 48,
5–13.
16. WHO. 2015 Chapter 5: Infectious diseases. In Health
in 2015: from MDGs, millennium development
goals to SDGs, sustainable development goals, pp.
101–130. Geneva, Switzerland: World Health
Organization. See http://www.who.int/gho/
publications/mdgs-sdgs/MDGs-SDGs2015_chapter5.
pdf?ua=1.
17. Maudlin I, Eisler MC, Welburn SC. 2009 Neglected
and endemic zoonoses. Phil. Trans. R. Soc. B 364,
2777–2787. (doi:10.1098/rstb.2009.0067)
18. FAO. 2014 Global livestock production and health
atlas. Rome, Italy: FAO. See http://kids.fao.org/
glipha/.
19. WHO. 2010 World Health Statistics, 2010. Geneva,
Switzerland. See http://www.who.int/whosis/
whostat/EN_WHS10_Full.pdf?ua=1.
20. WHO. 2008 International Health Regulations (2005),
2nd edn. Geneva, Switzerland: World Health
Organization. See http://www.who.int/ihr/
9789241596664/en/.
21. Global Health Security Agenda. 2016 Global Health
Security Agenda. See https://ghsagenda.org.
22. The World Bank. 2010 People, pathogens and our
planet. Volume 1: Towards a One Health approach
for controlling zoonotic diseases. Washington, DC:
The International Bank for Reconstruction and
Development/The World Bank. See http://
siteresources.worldbank.org/INTARD/Resources/PPP_
Web.pdf.23. United Nations. 2016 UN High-Level Panel on the
Global Response to Health Crises. Protecting
humanity from future health crises. New York, NY:
United Nations.
24. Burkle Jr FM. 2015 Global health security demands
a strong international health regulations treaty and
leadership from a highly resourced World Health
Organization. Disaster Med. Public Health Prep. 9,
568–580. (doi:10.1017/dmp.2015.26)
25. Pan American Health Organization. 2016 Inter-
American Ministerial Meeting on Health and
Agriculture: One Health and the Sustainable
Development Goals, Asuncion, Paraguay, 21–22 July
2016. Washington, DC: Pan American Health
Organization.
26. Pieracci EG et al. 2016 Prioritizing zoonotic diseases
in Ethiopia using a one health approach. One Health
2, 131–135. (doi:10.1016/j.onehlt.206.09.001)
27. Halliday J et al. 2012 Bringing together emerging
and endemic zoonoses surveillance: shared
challenges and a common solution. Phil.
Trans. R. Soc. B 367, 2872–2880. (doi:10.1098/rstb.
2011.0362)
28. Swanson RC et al. 2015 Strengthening health
systems in low-income countries by enhancing
organizational capacities and improving institutions.
Global. Health 11, 5. (doi:10.1186/s12992-015-
0090-3)
29. WHO. 2014 High level meeting on building resilient
systems for health in Ebola-affected countries,
10–11 December 2014. Geneva, Switzerland: World
Health Organization. See http://www.who.int/
mediacentre/events/meetings/2014/ebola-health-
systems/en/
30. Dzingirai V et al. 2016 Zoonotic diseases: who gets
sick, and why? Explorations from Africa. Crit. Public
Health 27, 97–110. (doi:10.1080/09581596.2016.
1187260)
31. Laurie EW. 2015 The embodied politics of health in
Dar Es Salaam, Tanzania. PhD thesis, University of
Glasgow, UK.
32. Farmer P. 2005 Pathologies of power: health, human
rights, and the new war on the poor. Berkeley, CA:
University of California Press.
33. Farmer P. 2001 Infections and inequalities: the
modern plagues. Berkeley, CA: University of
California Press.
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
372:20160168
1034. Chami GF, Kontoleon AA, Bulte E, Fenwick A,
Kabatereine NB, Tukahebwa EM, Dunne DW. 2016
Profiling nonrecipients of mass drug administration
for schistosomiasis and hookworm infections: a
comprehensive analysis of praziquantel and
albendazole coverage in community-directed
treatment in Uganda. Clin. Infect. Dis. 62, 200–207.
(doi:10.1093/cid/civ829)
35. WHO. 2008 Closing the gap in a generation.
Health equity through action on the social
determinants of health. Commission on Social
Determinants of Health, Final Report. See http://
www.who.int/social_determinants/
thecommission/finalreport/en/.
36. Marmot M. 2007 Achieving health equity: from root
causes to fair outcomes. Lancet 370, 1153–1163.
(doi:10.1016/s0140-6736(07)61385-3)
37. Scheil-Adlung X (ed.). 2015 Global evidence on
inequities in rural health protection. New data on
rural deficits in health coverage. ESS document no.
47. Geneva, Switzerland: International Labour
Office.
38. Miller MA, Sentz JT. 2006 Vaccine-preventable
diseases. In Disease and mortality in Sub-Saharan
Africa (eds DT Jamison, RG Feachem, MW Makgoba,
ER Bos, FK Baingana, KJ Hofman, KO Rogo), 2nd
edn, chapter 12. Washington, DC: The International
Bank for Reconstruction and Development/The
World Bank. See https://www.ncbi.nlm.nih.gov/
books/NBK2284/.
39. Bardosh K. 2016 One Health: science, politics and
zoonotic disease in Africa. Abingdon, UK: Earthscan
Routledge.
40. Hampson K, Dobson A, Kaare M, Dushoff J, Magoto
M, Sindoya E, Cleaveland S. 2008 Rabies exposures,
post-exposure prophylaxis and deaths in a region of
endemic canine rabies. PLoS Negl. Trop. Dis. 2, e339.
(doi:10.1371/journal.pntd.0000339)
41. Sambo M, Cleaveland S, Ferguson H, Lembo T,
Simon C, Urassa H, Hampson K. 2013 The burden of
rabies in Tanzania and its impact on local
communities. PLoS Negl. Trop. Dis. 7, e2510.
(doi:10.1371/journal.pntd.0002510)
42. Mtema Z et al. 2016 Mobile phones as surveillance
tools: implementing and evaluating a large-scale
intersectoral surveillance system for rabies in
Tanzania. PLoS Med. 13, e1002002. (doi:10.1371/
journal.pmed.1002002)
43. Vigilato MAN, Clavijo A, Knobl T, Silva HMT, Cosivi
O, Schneider MC, Leanes LF, Belotto AJ, Espinal MA.
2013 Progress towards eliminating canine rabies:
policies and perspectives from Latin America and
the Caribbean. Phil. Trans. R. Soc. B 368, 20120143.
(doi:10.1098/rstb.2012.0143)
44. Dean AS, Crump L, Greter H, Schelling E, Zinsstag J.
2012 Global burden of human brucellosis: a
systematic review of disease frequency. PLoS Negl.
Trop. Dis. 6, e1865. (doi:10.1371/journal.pntd.
0001865)
45. Rubach MP, Halliday JEB, Cleaveland S, Crump JA.
2013 Brucellosis in low-income and middle-income
countries. Curr. Opin. Infect. Dis. 26, 404–412.
(doi:10.1097/QCO.0b013e3283638104)46. de Vries SG, Visser BJ, Nagel IM, Goris MG,
Hartskeerl RA, Grobusch MP. 2014 Leptospirosis in
sub-Saharan Africa: a systematic review.
Int. J. Infect. Dis. 28, 47–64. (doi:10.1016/j.ijid.
2014.06.013)
47. Vanderburg S, Rubach MP, Halliday JE, Cleaveland S,
Reddy EA, Crump JA. 2014 Epidemiology of Coxiella
burnetii infection in Africa: a OneHealth systematic
review. PLoS Negl. Trop. Dis. 8, e2787. (doi:10.1371/
journal.pntd.0002787)
48. Allan KJ, Biggs HM, Halliday JE, Kazwala RR, Maro
VP, Cleaveland S, Crump JA. 2015 Epidemiology of
leptospirosis in Africa: a systematic review of a
neglected zoonosis and a paradigm for ‘One Health’
in Africa. PLoS Negl. Trop. Dis. 9, e0003899. (doi:10.
1371/journal.pntd.0003899)
49. Maina AN, Farris CM, Odhiambo A, Jiang J, Laktabai
J, Armstrong J, Holland T, Richards AL, O’Meara WP.
2016 Q fever, scrub typhus, and rickettsial diseases
in children, Kenya, 2011–2012. Emerg Infect. Dis.
22, 883. (doi:10.3201/eid2205.150953)
50. Maina AN et al. 2012 Rickettsia felis infection in
febrile patients, western Kenya, 2007–2010. Emerg.
Infect. Dis. 18, 328–331. (doi:10.3201/eid1802.
111372)
51. D’Acremont V et al. 2014 Beyond malaria—causes
of fever in outpatient Tanzanian children.
N. Engl. J. Med. 370, 809–817. (doi:10.1056/
NEJMoa1214482)
52. Njeru J, Henning K, Pletz MW, Heller R, Neubauer
H. 2016 Q fever is an old and neglected zoonotic
disease in Kenya: a systematic review. BMC
Public Health 16, 297. (doi:10.1186/s12889-016-
2929-9)
53. Njeru J et al. 2016 Human brucellosis in febrile
patients seeking treatment at remote hospitals,
northeastern Kenya, 2014–2015. Emerg. Infect. Dis.
22, 2160–2164. (doi:10.3201/eid2212.160285)
54. Ki-Zerbo GA, Tall F, Nagalo K, Ledru E, Durand G,
Patey O. 2000 Rickettsiosis and Q fever in pyretic
patients hospitalized at the Bobo-Dioulasso Hospital
(Burkina Faso). Med. Mal. Infect. 30, 270–274.
(doi:10.1016/S0399-077X(00)89140-4)
55. Bhatt S. 2015 The effect of malaria control on
Plasmodium falciparum in Africa between 2000 and
2015. Nature 526, 207–211. (doi:10.1038/
nature15535)
56. Odiit M, Shaw A, Welburn SC, Fevre EM, Coleman
PG, McDermott JJ. 2004 Assessing the patterns of
health-seeking behaviour and awareness among
sleeping-sickness patients in eastern Uganda. Ann.
Trop. Med. Parasitol. 98, 339–348. (doi:10.1179/
000349804225003389)
57. Allan KJ. 2016 Leptospirosis in northern Tanzania:
investigating the role of rodents and ruminant
livestock in a neglected public health problem. PhD
thesis, University of Glasgow, UK. See http://theses.
gla.ac.uk/view/creators/Allan=3AKathryn_
J=2E=3A=3A.html.
58. Ducrotoy M et al. 2015 Brucellosis in sub-Saharan
Africa: current challenges for management,
diagnosis and control. Acta Trop. 165, 179–193.
(doi:10.1016/j.actatropica.2015.10.023)59. de Glanville WA et al. 2017 Poor performance of
the rapid test for human brucellosis in health
facilities in Kenya. PLoS Negl. Trop. Dis. 11,
e0005508. (doi:10.1371/journal.pntd.0005508)
60. FAO. 2015 Regional workshop on brucellosis control
in Central Asia and Eastern Europe. FAO Animal
Production and Health Report No. 8. Rome, Italy:
Food and Agriculture Organization of the United
Nations. See http://www.fao.org/3/a-i4387e.pdf.
61. Viana M, Shirima GM, John KS, Fitzpatrick J,
Kazwala RR, Buza JJ, Cleaveland S, Haydon DT,
Halliday JE. 2016 Integrating serological and genetic
data to quantify cross-species transmission:
brucellosis as a case study. Parasitology 143,
821–834. (doi:10.1017/s0031182016000044)
62. Roth F, Zinsstag J, Orkhon D, Chimed-Ochir G,
Hutton G, Cosivi O, Carrin G, Otte J. 2003 Human
health benefits from livestock vaccination for
brucellosis: case study. Bull. World Health Organ.
81, 867–876.
63. Sergeant ES. 1992 Leptospirosis vaccination in beef
cattle: use of decision tree analysis. N. Z. Vet. J. 40,
62–65. (doi:10.1080/00480169.1992.35699)
64. Durski KN, Jancloes M, Chowdhary T, Bertherat E.
2014 A global, multi-disciplinary, multi-sectorial
initiative to combat leptospirosis: Global
Leptospirosis Environmental Action Network
(GLEAN). Int. J. Environ. Res. Public Health 11,
6000–6008. (doi:10.3390/ijerph110606000)
65. Courcoul A, Hogerwerf L, Klinkenberg D, Nielen M,
Vergu E, Beaudeau F. 2011 Modelling effectiveness
of herd level vaccination against Q fever in dairy
cattle. Vet. Res. 42, 68. (doi:10.1186/1297-9716-42-
68)
66. Hogerwerf L, van den Brom R, Roest HIJ, Bouma A,
Vellema P, Pieterse M, Dercksen D, Nielen M. 2011
Reduction of Coxiella burnetii prevalence by
vaccination of goats and sheep, the Netherlands.
Emerg. Infect. Dis. 17, 379–386. (doi:10.3201/
eid1703.101157)
67. Knight-Jones TJ, Edmond K, Gubbins S, Paton DJ.
2014 Veterinary and human vaccine evaluation
methods. Proc. R. Soc. B 281, 20132839. (doi:10.
1098/rspb.2013.2839)
68. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I,
Petticrew M. 2008 Developing and evaluating
complex interventions: the new Medical Research
Council Guidance. BMJ 337, a1655. (doi:10.1136/
bmj.a1655)
69. Pappas G, Papadimitriou P, Akritidis N, Christou L,
Tsianos EV. 2006 The new global map of human
brucellosis. Lancet Infect. Dis. 6, 91–99. (doi:10.
1016/s1473-3099(06)70382-6)
70. WHO, FAO, OIE. 2003 Brucellosis in humans and
animals. Geneva, Switzerland: World Health
Organization. See http://www.who.int/csr/resources/
publications/Brucellosis.pdf.
71. Godfroid J, Kasbohrer A. 2002 Brucellosis in the
European Union and Norway at the turn of the
twenty-first century. Vet. Microbiol. 90, 135–145.
(doi:10.1016/S0378-1135(02)00217-1)
72. Avila-Calderon ED, Lopez-Merino A, Sriranganathan
N, Boyle SM, Contreras-Rodriguez A. 2013 A
rstb.royalsocietypublishing.org
Ph
11history of the development of Brucella vaccines.
Biomed. Res. Int. 2013, 743509. (doi:10.1155/2013/
743509)
73. Welburn SC, Beange I, Ducrotoy MJ, Okello AL. 2015
The neglected zoonoses—the case for integrated
control and advocacy. Clin. Microbiol. Infect. 21,
433–443. (doi:10.1016/j.cmi.2015.04.011)
74. GALVmed. 2016 Protecting livestock, improving
human lives. See https://www.galvmed.org/en/
about-us/our-approach/.
75. Townsend SE et al. 2013 Designing programs for
eliminating canine rabies from islands: Bali,Indonesia as a case study. PloS Negl. Trop. Dis. 7,
e2372. (doi:10.1371/journal.pntd.0002372)
76. Zinsstag J, Durr S, Penny MA, Mindekem R, Roth F,
Menendez Gonzalez S, Naissengar S, Hattendorf J.
2009 Transmission dynamics and economics of
rabies control in dogs and humans in an African
city. Proc. Natl Acad. Sci. USA 106, 14 996–15 001.
(doi:10.1073/pnas.0904740106)
77. Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri
I, Lankester F, Lembo T, Meyers LA, Paltiel AD,
Galvani AP. 2014 Cost-effectiveness of canine
vaccination to prevent human rabies in ruralTanzania. Ann. Intern. Med. 160, 91–100. (doi:10.
7326/m13-0542)
78. Bill and Melinda Gates Foundation. Integrated
delivery strategy overview. http://www.
gatesfoundation.org/What-We-Do/Global-
Development/Integrated-Delivery.
79. Schelling E, Wyss K, Be´chir M, Moto DD, Zinsstag
J. 2005 Synergy between public health and
veterinary services to deliver human and animal
health interventions in rural low income settings.
BMJ 331, 1264–1267. (doi:10.1136/bmj.331.
7527.1264) il.Trans.R.Soc.B
372:20160168
